Vistagen Therapeutics, Inc. (VTGN) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day. Thank you for standing by. Welcome to this agenda predicts third quarter fiscal year 2025 corporate update conference call. At this time, all participants on the list are normally mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automatic message advising your hand is raised. Please note that today's conference is being recorded. I will now hand the conference over to speaker host, Mark McPartland, please go ahead. Thank you, operator. Good afternoon, everyone, and welcome to Vistagen's fiscal year 2025 third quarter corporate update conference call and webcast. Earlier this afternoon, we issued a press release for the third quarter of our fiscal year 2025 into December 31st, 2024, providing an overview of our progress across our lead clinical neuroscience programs. We encourage you to review the release, which can be found in the investor section of our website. Based on the current expectations information, we will make forelooking statements regarding our business during today's call. These forelooking statements speak only as of today, except as required by law, we do not assume any duty to update any forelooking statements made today and or in future. Of course, forelooking statements include risks and uncertainties, and our actual results could differ materially from those anticipated by any forward-looking statements that we make today. Additional information concerning risks and factors that could affect our business and financial results will be included in our fiscal year 2025 third quarter Form 10-Q for the period ending December 31, 2020. For and in future filings, we will make with the SEC from t...